ArticleParasites & vectors2025
P-glycoprotein-9-mediated multidrug tolerance in Caenorhabditis elegans.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe active drug efflux pumps P-glycoproteins (PGPs) are the cornerstones of multidrug resistance in many organisms. In parasitic helminths, resistance to macrocyclic lactones (MLs) has been associated with pgp regulation and structural defects in amphids. In Caenorhabditis elegans, the nuclear hormone receptor (NHR)-8 also influences xenobiotic tolerance by regulating pgp genes. However, the specific contribution of individual transporters and their regulation remain poorly defined. We recently demonstrated that PGP-9 specifically contributes to ivermectin (IVM) tolerance in an IVM-resistant C. elegans strain. This study aimed to explore the role of PGP-9 in drug efflux in C. elegans.
methodsWe used the IVM-resistant and dye-filling defective (Dyf) C. elegans strain IVR10 and a pgp-9 IVR10 mutant to assess larval development under MLs (eprinomectin (EPR) and moxidectin (MOX)) and tunicamycin (TM). We evaluated whether the Dyf phenotype was affected by pgp-9 deletion. We investigated the role of NHR-8 in regulating pgp-9 via reverse-transcription quantitative polymerase chain reaction (RT-qPCR) and by assessing ML sensitivity in an IVR10 nhr-8 mutant. Additional candidate regulators of pgp-9 were also tested.
resultsIVR10 displayed resistance to MLs and to TM, while pgp-9 deletion restored full drug sensitivity despite the persistence of the Dyf phenotype. Although nhr-8 deletion in IVR10 increased IVM sensitivity, pgp-9 expression was not significantly altered in that strain or IVR10. Interfering RNA (RNAi) targeting pgp-9 in the nhr-8 mutant further increased IVM sensitivity, uncoupling PGP-9 from NHR-8 regulation. Candidate NHRs did not affect IVM tolerance in N2B.
conclusionsThese results provide the first direct evidence that PGP-9 is necessary for multidrug tolerance in C. elegans, independently of amphid structural defects and NHR-8 regulation. These findings uncover a novel mechanism supporting drug resistance and highlight PGP-9 as a potential therapeutic target to improve ML treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.